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Background: Septic thrombophlebitis increases patient morbidity and mortality following metastatic infections,
pulmonary emboli, and/or septic shock. Central venous catheter (CVC) removal for occult septic thrombophlebitis
challenges current strategy in neutropenic patients.
Patients and methods: We prospectively evaluated infection-related mortality in 100 acute leukemia patients, with
CVC-related bloodstream infection (CRBSI) after chemotherapy, who systematically underwent ultrasonography to
identify the need for catheter removal. Their infection-related mortality was compared with that of a historical cohort of
100 acute leukemia patients, with CRBSI after chemotherapy, managed with a clinically driven strategy. Appropriate
antimicrobial therapy was administered in all patients analyzed.
Results: In the prospective series, 30/100 patients required catheter removal for ultrasonography-detected septic
thrombophlebitis after 1 median day from BSI onset; 70/100 patients without septic thrombophlebitis retained their
CVC. In the historical cohort, 60/100 patients removed the catheter (persistent fever, 40 patients; persistent BSI, 10
patients; or clinically manifest septic thrombophlebitis, 10 patients) after 8 median days from BSI onset; 40/100 patients
retained the CVC because they had not clinical ﬁndings of complicated infection. At 30 days median follow-up, one
patient died for infection in the ultrasonography-assisted group versus 17 patients in the historical cohort (P < 0.01).
With the ultrasonography-driven strategy, early septic thrombophlebitis detection and prompt CVC removal decrease
infection-related mortality, whereas clinically driven strategy leads to inappropriate number, reasons, and timeliness of
CVC removal.
Conclusion: Ultrasonography is an easy imaging diagnostic tool enabling effective and safe management of patients
with acute leukemia and CRBSI.
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introduction
Long-term central venous catheter (CVC) insertion has
improved the management of patients with acute leukemia by
facilitating administration of cytotoxic drugs, antimicrobials,
blood products, and parenteral hyperalimentation [1]. Many
types of problems are reported following the CVC insertion
[1]. Bloodstream infection (BSI) and thrombosis are the most
important long-term complications [1, 2]. Catheter-related
infection and thrombosis should not be seen as separate
entities, given their bidirectional relationship [1, 2]. A number
of bacteria and fungi bind to ﬁbronectin and other serum
components that coat catheters by means of specialized
adhesive matrix molecules [1, 2]. In the bioﬁlm created by the
protein sheath, the pathogens may exceed a critical amount
with release of microorganisms in the blood and, consequently,
BSI [1–3]. In such instances, thrombosis should be assumed to
be infected, establishing the inﬂammatory entity of septic
thrombophlebitis [1, 3]. Metastatic infections, massive septic
pulmonary emboli, and/or septic shock may complicate
this condition, thus increasing patient morbidity and mortality
[3, 4].
A 10%–15% incidence of CVC-associated clinically manifest
venous thrombosis and a 30%–70% incidence of CVC-
associated subclinical venous thrombosis are reported among
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cancer patients with neutropenic fever [1–7]. Consequently, a
number of such patients could have no physical examination
ﬁndings suggesting catheter-related septic thrombophlebitis
[5–7] This condition requires speciﬁc management, which
includes prolonged antimicrobial administration,
anticoagulants, and, especially, catheter removal. Few data exist
regarding the impact of strict imaging surveillance, of CVC
sites, on the identiﬁcation of the most appropriate time for
removing complicated catheters, and/or the subpopulation of
patients who would beneﬁt most from such intervention [1–7].
In view of the wide use of ultrasonography to detect
thrombosis [8, 9], we conducted a prospective study in acute
leukemia patients with CVC-related BSI, undergone
systematically ultrasonography to identify the need for catheter
removal. We then compared 30-day mortality in these patients
with that of a historical cohort of patients with acute leukemia,
in whom CVC-related BSIs were conventionally managed (the
decision for catheter removal was based on clinical criteria) [1].
We tested the hypothesis that treatment strategy, planned on
the basis of an ultrasonography-driven approach, resulted in a
better outcome than a clinically driven approach, for the early
detection of septic thrombophlebitis by ultrasonography and,
consequently, the prompt removal of CVC, contributing to
infected thrombus rapid dissolution thereby avoiding septic
thrombophlebitis lethal complications [1, 3, 4, 9].
patients and methods
study design
Four hundred consecutive patients with newly diagnosed acute leukemia
[10], referred to our institution between January 2004 and December 2009,
were screened for enrollment. Inclusion criteria were (i) age <75 years, (ii)
World Health Organization performance score 0–3, (iii) a long-term CVC
in situ (expected permanence ≥2 weeks), (iv) administration of
chemotherapy inducing neutropenia, and (v) CVC-related BSI. Patients for
whom appropriate data were not available, patients not receiving at least 60
h of effective antimicrobial treatment on the basis of in vitro susceptibility
(without delay or reduction), or patients not receiving heparin at standard
dosage [1, 9, 11] in case of venous thrombosis (if the platelet count was <
30 000/μl, anticoagulant was not administered) were excluded. In this
group, all patients systematically underwent ultrasonography screening for
CVC-related septic thrombophlebitis. Ultrasonography ﬁndings of septic
thrombophlebitis prompted the immediate CVC removal.
A historical cohort of 400 patients with newly diagnosed acute leukemia
[10], and referred to our institution between January 1997 and December
2003, was considered for the comparison. This control group was
retrospectively collected. Inclusion and exclusion criteria were the same as
for the ultrasonography-assisted group, except that catheter site
ultrasonography was not routinely carried out. In this cohort, CVC was
removed for (i) clinical ﬁndings of septic thrombophlebitis, (ii) persistent/
recurrent bacteremia or fungemia, and/or (iii) persistent/recurrent fever [1,
11].
The study took place at the Hematology Division of the University of
Naples ‘Federico II’ (Italy), after institutional review board approval.
Patients were informed of the study aim. Informed consent was obtained
from all patients studied, according to the Helsinki declaration.
All patients were hospitalized from the start of chemotherapy and
received antimicrobial prophylaxis. An untunneled heparin-coated Vialon
catheter (Becton-Dickinson) was inserted in the internal jugular or
subclavian vein by the same specialized medical staff, using the Seldinger
technique, before chemotherapy administration [12]. In the event of
neutropenic fever, all patients underwent detailed history and physical
examination, complete blood study, and paired blood samples drawn from
CVC and a peripheral vein for cultures (10 ml of blood per bottle; signal
system, Oxoid, Hants, UK) repeated every 72 h until fever disappearance.
In both the groups of patients, CVC-related BSI was deﬁned as isolation of
the same phenotypic microorganism from at least one catheter sample and
one peripheral venous sample, with no other identiﬁable source of
infection [1, 11]. Additional assessments included blood samples for
cultures every 72 h until infection eradication, and further evaluations if
clinically indicated.
Thus, all patients included in the study had positive blood culture
results. In the historical cohort, septic thrombophlebitis was deﬁned as
being present if pain, induration, erythema, exudates and/or asymmetric
venous distension involving the catheter insertion site, and/or ipsilateral
arm and/or chest were detected by physical examination [1, 7, 11]. In the
prospective series, septic thrombophlebitis was considered present if a clear
intraluminal thrombus, i.e. a ≥0.5 cm echogenic intravascular mass, was
visualized at gray-scale ultrasonography of CVC area [3–8].
ultrasonography procedures
In the prospective series, a hematologist (MP) [13] carried out
ultrasonography scans of the bilateral internal jugular, subclavian, and
axillary veins, within 24 h of BSI onset, using a scanner (iU22; Philips
Healthcare, Bothell, WA) equipped with a 9-3 MHz broadband linear
probe. The ultrasonography investigations were carried out directly at the
patient’s bedside and were repeated every 3 days until infection resolution.
Each vessel was scanned in real-time B-mode and color Doppler, according
to a standardized protocol [5–8]. Patients with uninterpretable
ultrasonography images because of insufﬁcient views or poor image quality
were excluded [1, 3–9].
statistical analysis
Our hypothesis was that in cohorts of at least 98 patients each, statistical
signiﬁcance could be achieved if an absolute difference of 15% in overall
survival between the ultrasonography-driven and the clinically driven
approaches was reached, with an 80% statistical power and a 5%
signiﬁcance level (α error = 0.05, β error = 0.20).
The time-related dependent variable used in the trial was overall
survival. Death from any cause was considered an event. Overall survival
was calculated from the date of BSI onset to the date of the event or last
follow-up visit 30 days after BSI onset; overall survival was estimated by the
Kaplan–Meier method. For the statistical evaluations, the log-rank test, χ2
test, and t-test were carried out. P values <0.05 were deemed statistically
signiﬁcant.
results
patient enrollment
From 2004 to 2009, 110/400 (27%) consecutive patients with
acute leukemia received a diagnosis of CVC-related BSI after
induction chemotherapy; 10 of them were excluded. In the
historical cohort, 108 patients with acute leukemia had a
diagnosis of CVC-related BSI after induction chemotherapy; 8
of them were excluded. The remaining 100 patients of the
ultrasonography-assisted group and the 100 patients of the
historical cohort constituted the study population (Figure 1).
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patient demographics and characteristics
The two series were comparable with respect to baseline
prognostic variables (acute myeloid leukemia treated with
cytarabine-based regimens, 80% of patients; acute
lymphoblastic leukemia treated with anthracycline-based
regimens, the patient remainder). Median time with neutrophil
count < 500/μl and platelet count < 10 000/μl was 11 days and
10 days, respectively (Table 1). The organisms responsible for
BSI differed between the two groups: 60 patients with Gram-
positive bacteremia, 35 patients with Gram-negative
bacteremia, and 5 patients with fungemia in the historical
cohort versus 50 patients with Gram-positive bacteremia, 41
patients with Gram-negative bacteremia, and 9 patients with
fungemia in the ultrasonography-assisted group. The rates of
antibiotic-resistant Gram-positive bacteria and of Gram-
negative bacteria producing extended-spectrum β-lactamases
are shown in Table S1 (available as supplementary data in
Annals of Oncology online). Overall, median time between
CVC insertion and BSI onset was 18 days.
treatment of CVC-related BSI
Overall, 168 patients received antibiotic therapy, 14 patients
antifungal therapy, and 25 patients heparin therapy.
Daptomycin, linezolid, tigecycline, and caspofungin were
administered only in patients in the prospective series. Despite
a similar median number of days of i.v. antibiotics
(supplemental Table S2, available at Annals of Oncology
online), there was signiﬁcant difference between the two groups
with regard to the duration of antibiotic treatments, owing to
more early events in the historical cohort compared with the
prospective series (see below). There was no signiﬁcant
difference between the two groups in terms of duration of
antifungal and heparin treatment.
Among patients surviving at 30 days follow-up, median time
to achieve complete clinical and microbiological response was
10 days (range, 4–15 days) in the historical cohort and 9 days
(range, 3–10 days) in the ultrasonography-assisted group.
removal of CVC
The number of CVCs removed differed signiﬁcantly between
the two groups. Sixty patients (Gram-positive bacteremia, 35
patients; Gram-negative bacteremia, 20 patients; and fungemia,
5 patients) in the historical cohort versus 30 patients (Gram-
negative bacteremia, 15 patients; Gram-positive bacteremia, 10
patients; and fungemia, 5 patients) in the ultrasonography-
assisted group required catheter removal (P < 0.01).
The time to CVC removal since BSI onset differed
signiﬁcantly between the two groups. CVCs were removed after
a median of 8 days (range, 4–9 days) inthe historical cohort
versus 1 day (range, 1–3 days) in the ultrasonography-assisted
group (P < 0.01). Median time from BSI onset to CVC removal
for the speciﬁc pathogens isolated in the two series is shown in
Table 2.
The reasons for removing the CVCs differed signiﬁcantly
between the two groups. The reason for removing CVCs in the
prospective series was ultrasonography-detected septic
thrombophlebitis (30/30, 100%). In the historical cohort, CVCs
were removed following persistent or recurrent fever (40/60,
67%), persistent or recurrent bacteremia or fungemia (10/60,
16%), or clinically manifest septic thrombophlebitis (10/60,
16%).
Thus, in the historical cohort, the cumulative incidence of
clinically manifest septic thrombophlebitis was 10%.
Figure 1. Flow-chart of the study. AL, acute leukemia; CVC, central venous catheter.
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ultrasonography scanning results
In the prospective series, all patients received the scheduled
imaging surveillance. A median of four ultrasonography
examinations was carried out per patient (range, 3–6), each
complete examination requiring 30 min on average (range, 20–
40 min). Septic thrombophlebitis was detected by systematic
ultrasonographic scans of the jugular, subclavian, and/or
axillary veins in 30/100 patients. The locations of the thrombi
were to the subclavian vein in 10 patients, to the internal
jugular vein in 10 patients, and to two or more veins in 10
patients (Figure S1, available in Annals of Oncology online).
None of the patients receiving diagnosis of septic
thrombophlebitis showed clinical signs or symptoms of
thrombophlebitis.
In the patients of both the series with a diagnosis of septic
thrombophlebitis, blood cultures yielded Staphylococcus spp.
(19 cases), Enterobacteriaceae spp. (16 cases), and Candida
spp. (5 cases). The distribution of the pathogens of patients
with a diagnosis of septic thrombophlebitis in the two series is
illustrated in supplemental Figure S2 (available at Annals of
Oncology online). A similar number of patients with septic
thrombophlebitis related to Staphylococcus spp. was observed
in the two series. In contrast, ultrasonography identiﬁed more
patients with septic thrombophlebitis related to
Enterobacteriaceae spp. and Candida spp. than the physical
examination. In particular, 15 cases of septic thrombophlebitis
related to Escherichia coli and 5 to Candida parapsilosis were
detected in the ultrasonography-assisted group versus 1 case
related to E. coli and no septic thrombophlebitis related to
Candida spp. in the historical cohort.
In the prospective series, the median time between BSI onset
and ultrasonography-detected septic thrombophlebitis was 1
day (range, 1–3 days). In the historical cohort, the median time
between BSI onset and physical examination-detected septic
thrombophlebitis was 8 days (range, 7–10 days). This
difference reﬂected the very early removal of CVCs in the
prospective series compared with removal time in the historical
cohort (Figure 2).
overall survival of patients analyzed
The median observation time was 30 days (range, 3–30 days)
in both the groups. At a 30-day follow-up, the overall survival
of the entire population was 87%: 25 of the 200 patients
analyzed had died. The 25 events observed were not evenly
Table 1. Baseline characteristics of the population analyzed
Variable Ultrasonography-
assisted group
Historical
cohort
P
No. of patients 100 100 NS
Median age, years (range) 51 (18–74) 53 (18–74) NS
Male/female 45/55 47/53 NS
Hematological disease NS
Acute myeloid leukemia 82 80
Acute lymphoblastic leukemia 18 20
FAB subtypes NS
M0–M2 40 40
M3 2 3
M4–M7 40 37
L1–L2 13 15
L3 5 5
WHO status NS
0–1 75 75
2–3 25 25
Chemotherapy treatment NS
Cytarabine-based regimen 82 80
Anthracycline-based regimen 18 20
Central venous catheter type NS
Untunneled 100 100
Double lumen 45 40
Tri lumen 55 60
Central venous catheter site NS
Jugular vein 40 35
Subclavian vein 60 65
Post-chemotherapy aplasia NS
Neutropenia <500/μl 100 100
Prolonged neutropenia, days
(range)
11 (7–28) 11 (7–28)
Thrombocytopenia <10 000/μl 100 100
Prolonged thrombocytopenia,
days (range)
10 (7–20) 10 (7–20)
Unless otherwise indicated, data refer to the number of patients.
FAB, French–American–British revised criteria; NS, not signiﬁcant; WHO,
World Health Organization.
Table 2. Removal of central venous catheters in the patients analyzed
Variable Ultrasonography-
assisted group
Historical
cohort
P
No. of CVC removed 30 60 <0.01
Causative pathogens of
bloodstream infections in
patients removing CVC
NS*
Gram-positive 10 35 –
Gram-negative 15 20 –
Fungus 5 5 –
Time to CVC removal since
bloodstream infection onset
Median, days (range)
1 (1–3) 8 (4–9) <0.01
Time to CVC removal since
bloodstream infection onset,
for the speciﬁc pathogens
isolated
<0.01
Gram-positive
Median, days (range) 3 (2–3) 8 (4–9) –
Gram-negative
Median, days (range) 1 (1–3) 7 (5–8) –
Fungus
Median, days (range) 1 (1–3) 6 (5–6) –
Reasons for removing CVC <0.01
Persistent/recurrent fever 0 40 –
Persistent/recurrent bacteremia
or fungemia
0 10 –
Septic thrombophlebitis 30 10 –
NB. Unless otherwise indicated, data refer to the number of patients.
CVC, central venous catheter.
*P value = 0.07.
Annals of Oncology original articles
Volume 23 | No. 8 | August 2012 doi:10.1093/annonc/mdr588 | 
 at U
niversita di N
apoli on A
ugust 31, 2012
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
distributed in the two series. Death occurred in 5 of the 100
patients in the prospective series. Thus, patients in the
ultrasonography-assisted group achieved a 95% overall survival.
In contrast, 20 of the 100 patients in the historical cohort died.
Consequently, overall survival was 80% in the historical cohort
(P < 0.01; Figure 2). The causes of death were cerebral
hemorrhage (n = 1), underlying malignancy progression (n =
2), and BSI (n = 17) in the historical cohort and cerebral
hemorrhage (n = 2), underlying malignancy progression (n =
2), and BSI (n = 1) in the ultrasonography-assisted group.
Mortality rate was 34% (12/35) for Gram-negative bacteremia
(E. coli, nine patients; Acinetobacter baumannii, one patient;
Stenotrophomonas maltophilia, one patient; Klebsiella
pneumoniae, one patient), 3% (2/60) for Gram-positive
bacteremia (Corynebacterium jeikeium, one patient;
Staphylococcus haemolyticus, one patient), and 60% (3/5) for
fungemia (Candida parapsilosis, three patients) in the historical
cohort compared with 2% (1/50) for Gram-positive bacteremia
(S. haemoliticus) in the ultrasonography-assisted group. Thus,
infection-related mortality was 17% in the historical cohort
versus 1% in the ultrasonography-assisted group (P < 0.01).
discussion
CVC removal in neutropenic patients with BSI is controversial
[1, 4, 11, 14]. The clinically driven strategy—a standard
approach—leaves to the attending physician the decision to
remove the CVC on the basis of clinical ﬁndings suggestive of
complicated infection [1, 4, 11].
The present experience is the ﬁrst example so far reported of
ultrasonography-driven strategy in neutropenic patients with a
long-term CVC in situ and BSI [5–7]. This is a prospective
interventional trial based on the early identiﬁcation of the
settings of patients requiring CVC removal. At BSI onset, in
addition to the administration of adequate antimicrobial
therapy [1, 4, 11], a strict and prolonged surveillance of CVC
sites was carried out by using ultrasonography. Patients with
ultrasonography-detected septic thrombophlebitis [3–8]
underwent prompt CVC removal [4, 9]. Patients without septic
thrombophlebitis continued to undergo diagnostic work-up
that spared CVC removal.
Our ultrasonography-driven strategy seems to offer
advantages over a clinically driven strategy adopted in a
historical cohort of patients with CVC-related BSI,
balanced for clinical features to the patient prospective
series. First, early ultrasonographic identiﬁcation of septic
thrombophlebitis together with the prompt removal of
complicated catheter enabled an effective control of BSI. At
30 days follow-up, overall survival rate was signiﬁcantly
higher in patients in the ultrasonography-assisted group
than in patients of the historical cohort. Patients not
protected by ultrasonographic surveillance had a 17% risk
of infection-related mortality, with the majority of events
occurring relatively early. By contrast, the infection-related
mortality risk was 16% points lower in patients in the
ultrasonography-assisted group. Probably, the timeliness of
CVC removal represented the factor that inﬂuenced the
outcome in our study. Among patients with Gram-negative
bacteremias and candidemias in the prospective series,
CVCs were removed after 1 median day from the BSI
onset, which is signiﬁcantly different from the 7 median
days for Gram-negative bacteremias and the 6 median days
for candidemias in the historical cohort Table 2. Second,
ultrasonography was signiﬁcantly more effective in
identifying septic thrombophlebitis than physical
examination. We reported 30% of ultrasonography-detected
septic thrombophlebitis versus 10% of physical
examination-detected septic thrombophlebitis, with an
interval between onset of BSI and diagnoses of septic
thrombophlebites of 1 median day in the ultrasonography-
Figure 2. Probability of removing the central venous catheter in patients
with bloodstream infection after chemotherapy for acute leukemia, in the
historical cohort and in the ultrasonography-assisted group (A). Overall
survival of the entire population analyzed (B), and of patients in the
historical cohort (n = 100) and the ultrasonography-assisted group (n =
100) (C). Days, days from bloodstream infection onset; US,
ultrasonography. The number of patients without events at each time point
is given beneath the graph.
original articles Annals of Oncology
 | Picardi et al. Volume 23 | No. 8 | August 2012
 at U
niversita di N
apoli on A
ugust 31, 2012
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
assisted group versus 8 median days in the historical
cohort (P < 0.01). Physical examination is poorly able to
detect patients with such complication and it entails an
extent of false-negative results [5–7]. In our prospective
series, Candida non-albicans (5/9, 55%) and
Enterobacteriaceae spp. (15/37, 40%) were potent inductors
of septic thrombophlebitis compared with Staphylococcus
spp. (10/38, 26%). It is reasonable to assert that in the
historical cohort, occult septic thrombophlebitis was present
at the time of the ﬁrst days of BSI, and the nonremoval of
CVC together with the persistently infected intravascular
thrombus were the cause of the rapid clinical worsening.
Finally, we would like to underline the appropriateness of
criteria used for CVC removal in the prospective series, i.e.
ultrasonography-detected septic thrombophlebitis, compared
with criteria taken on clinical grounds [14]. Our
ultrasonography-driven strategy permitted a 50% reduction
in CVC removal, i.e. more salvages of CVCs, compared
with the clinically driven approach. The ability to predict
BSI unlike to be complicated by septic thrombophlebitis
permitted us to safely leave the CVC in situ. In the
prospective series of the 70 patients who did not remove
the CVC because the ultrasonography screening was
negative, only one died for BSI. On the contrary, the
clinically driven approach led to late and/or unnecessary
CVC removal, as reﬂected by a substantial increase in the
number of patients who died for infection in the historical
cohort despite the large number of CVCs removed.
Our study has several limitations. First, it is a single-center
nonrandomized study (comparison with retrospective series)
with a small number of events, which limits the statistical
results; hence, our ﬁndings need to be validated in a
prospective large trial. Second, the general improvement of the
management including the availability of new and effective
antimicrobial drugs [4] and the particular attention to CVC
removal for the existence of prospective trial by itself may have
substantially inﬂuenced the outcome of patients in the
prospective series. In the historical cohort, a too conservative
approach was used for CVC removal, likely accounting for the
deaths reported. Third, in this study, CVC-related BSIs were
diagnosed without knowing the differential time to positivity
between the blood samples [1, 4]. Fourth, the septic
thrombophlebitis high rate in the ultrasonography-assisted
group could be due to a selection of aggressive pathogens over
the 13-year study period [4, 11]. Fifth, anticoagulation therapy
role is not clear [1, 9] since several patients did not undergo
anticoagulants for severe thrombocytopenia. Sixth, none of our
patients who died underwent autopsy, which limits the
knowledge of the deﬁnitive cause of the event. Finally, a
number of patients were excluded from the ultrasonographic
study for poorly visualized vessels within the thorax [1, 9].
Others imaging tools could be used for diagnosing septic
thrombophlebitis [1, 9, 15].
In conclusion, septic thrombophlebitis is a hidden threat for
neutropenic patients with CVC in situ and BSI [1, 4, 9, 14].
Our study underlines the importance of including an imaging
modality in the frame of the diagnostic work-up to optimize
the treatment of these patients [5–7]. We propose
ultrasonography as new standard to scan CVC sites [1, 5–7, 9]
because it provides an early diagnosis of septic
thrombophlebitis. The ultrasonography is able to identify a
subset of patients who need prompt CVC removal to reduce
the risk of infection-related mortality [16, 17], and similarly
important, it is able to salvage CVCs in a relevant number of
patients.
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Racial disparities in Hodgkin’s lymphoma: a
comprehensive population-based analysis
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Background: Racial disparity has been investigated in a number of cancers; however, there remains a comparative
paucity of data in Hodgkin’s lymphoma (HL).
Patients and methods: We examined time-, age-, and gender-speciﬁc incidence, disease characteristics, and
survival across and within races for adolescent/adult HL (age 10–79 years) diagnosed during 1992–2007 in the SEER
13 registries.
Results: A total of 15 662 HL cases were identiﬁed [11 211 non-Hispanic whites, 2067 Hispanics, 1662 blacks, and
722 Asian/Paciﬁc Islanders (A/PI)]. Similar to whites, A/PIs had bimodal age-speciﬁc incidence, while blacks and
Hispanics did not. Further, HL was signiﬁcantly more common in Hispanics versus whites age >65 years (7.0/1 × 106
versus 4.5/1 × 106, respectively, P <0.01). By place of birth, US-born Hispanics and A/PIs age 20–39 years had higher
incidence of HL versus their foreign-born counterparts (P <0.05), however, rates converged age >40 years.
Interestingly, from 1992–1997 to 2003–2007, A/PI incidence rates increased >50% (P <0.001). Moreover, this increase
was restricted to US-born A/PI. We also identiﬁed a number of disease-related differences based on race. Finally, 5-,
10-, and 15-year overall survival rates were inferior for blacks and Hispanics compared with whites (P <0.005 and P
<0.001, respectively) and A/PI (P <0.018 and P <0.001, respectively). These differences persisted on multivariate
analysis.
Conclusion: Collectively, we identiﬁed multiple racial disparities, including survival, in adolescent/adult HL.
Key words: cancer, epidemiology, ethnicity, Hodgkin lymphoma, prognosis, race
introduction
Racial disparity has been investigated in a number of cancers
[1–10]. Many studies have noted signiﬁcant differences in
incidence rates, patient and disease-related characteristics, and/
or survival based on race. However, population-based survival
analyses of racial disparities have been reported mostly in solid
tumors (e.g. breast, colon, prostate, and lung) with recent
reports in non-Hodgkin’s lymphoma (HL) [6] and multiple
myeloma [10]. A comparative paucity of data are available in
adult HL.
In pediatric HL, Metzger et al. [11] found that disease-
related features and clinical characteristics did not differ
between races (white and black children). Furthermore, black
children with HL had lower event-free survival (EFS)
compared with white children, while both populations had
similar 5-year overall survival (OS). Studies examining racial
disparities in adult HL including age-speciﬁc HL incidence
patterns have been reported, however they have been smaller
scope (statewide), did not encompass all races (i.e. including
Hispanics and Asian/Paciﬁc Islanders (A/PI)), and/or did not
include analyses by place of birth [12, 13].
The overall incidence of HL varies greatly throughout the
world. Pathogenesis of this geographic discrepancy of HL
incidence is not known; however, environmental and lifestyle
factors have been theorized as potential factors [14]. A British
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